By Maggie Fick and Yadarisa Shabong (Reuters) -Drugmaker AstraZeneca lifted its annual sales and profit forecast for the ...

The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

Bitcoin's blistering rally rages on as the world's best known cryptocurrency scaled yet another record peak close to $90K ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

AstraZeneca now expects 2024 revenue and core earnings per share to grow by a high-teens percentage, from a previous forecast ...

AstraZeneca raised its full-year guidance after third-quarter results topped analysts' expectations, boosted by its cancer and diabetes medicines, and laid out plans for a multibillion-dollar ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

The boss of AstraZeneca has said the group takes the probe in China that saw the detention of its president in the country ...

AstraZeneca’s results were helped by resilient demand for its cancer and rare diseases medicines, after third-quarter results ...

Astrazeneca has raised its guidance for the full year despite issues surrounding its presence in China according to today's ...

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Tuesday a $3.5 billion capital investment in the United States, aiming to ...